Ipsen Innovation, 5 avenue du Canada, Z.I. Courtabœuf, Les Ulis 91190, France.
Ipsen Pharmsciences, 20 rue Ethé Virton, Dreux 28109, France.
Ther Deliv. 2021 Jan;12(1):55-76. doi: 10.4155/tde-2020-0079. Epub 2020 Dec 14.
Global cancer prevalence has continuously increased in the last decades despite substantial progress achieved for patient care. Cancer is no longer recognized as a singular disease but as a plurality of different ones, leading to the important choice of the drug administration route and promoting the development of novel drug-delivery systems (DDS). Due to their structural diversity, therapeutic cancer drugs present specific challenges in physicochemical properties that can adversely affect their efficacy and toxicity profile. These challenges are addressed by innovative DDS to improve bioavailability, pharmacokinetics and biodistribution profiles. Here, we define the drug delivery challenges related to oral, intravenous, subcutaneous or alternative routes of administration, and review innovative DDS, marketed or in development, that answer those challenges.
尽管在患者治疗方面取得了重大进展,但在过去几十年中,全球癌症的发病率仍持续上升。癌症不再被认为是一种单一的疾病,而是多种不同疾病的统称,这导致了药物给药途径的重要选择,并促进了新型药物传递系统(DDS)的发展。由于其结构多样性,治疗癌症的药物在理化性质方面具有特定的挑战,这些挑战可能会对其疗效和毒性特征产生不利影响。这些挑战通过创新的 DDS 来解决,以提高生物利用度、药代动力学和生物分布特征。在这里,我们定义了与口服、静脉内、皮下或其他给药途径相关的药物输送挑战,并回顾了已上市或正在开发的创新 DDS,以应对这些挑战。